Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
4.930
+0.070 (1.44%)
At close: May 8, 2026, 4:00 PM EDT
4.950
+0.020 (0.41%)
After-hours: May 8, 2026, 7:06 PM EDT
Aclaris Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts that cover Aclaris Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $11.33, which forecasts a 129.82% increase in the stock price over the next year. The lowest target is $9.00 and the highest is $16.
Price Target: $11.33 (+129.82%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aclaris Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 1 | 1 | 1 | 1 | 2 |
| Buy | 6 | 4 | 4 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 5 | 5 | 4 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $7 → $11 | Buy | Maintains | $7 → $11 | +123.12% | May 5, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +143.41% | May 5, 2026 |
| Wedbush | Wedbush | Buy Maintains $8 → $10 | Buy | Maintains | $8 → $10 | +102.84% | Apr 29, 2026 |
| Oppenheimer | Oppenheimer | Buy Initiates $10 | Buy | Initiates | $10 | +102.84% | Apr 16, 2026 |
| Wedbush | Wedbush | Buy Reiterates $8 | Buy | Reiterates | $8 | +62.27% | Mar 31, 2026 |
Financial Forecast
Revenue This Year
5.26M
from 7.83M
Decreased by -32.75%
Revenue Next Year
5.45M
from 5.26M
Increased by 3.63%
EPS This Year
-0.65
from -0.53
EPS Next Year
-0.69
from -0.65
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 10.5M | 12.6M | ||||||
| Avg | 5.3M | 5.5M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 34.2% | 139.4% | ||||||
| Avg | -32.7% | 3.6% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.50 | -0.47 | |||
| Avg | -0.65 | -0.69 | |||
| Low | -0.85 | -0.77 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.